Sweden is on track to become the first country in the world to meet the EU’s definition of smoke-free status — fewer than 5% of the population smoking daily. It will achieve this milestone not through prohibition, not through taxation alone, and not through public health campaigns, though all three have played supporting roles. Sweden will become smoke-free primarily because Swedish society developed an alternative to cigarettes decades before the rest of the world and adopted it at scale: snus, the oral tobacco product that provided the template for modern nicotine pouches.
The Swedish experience is the most important natural experiment in tobacco harm reduction that has ever been conducted, and it remains underappreciated in global health policy discussions. Male smoking rates in Sweden are among the lowest in Europe. Tobacco-related disease rates follow accordingly. These outcomes were achieved not by eliminating nicotine use but by redirecting it toward a product that carries substantially lower health risks than cigarettes.
The lessons for nicotine pouch regulation are direct. Pouches are, in most respects, snus without the tobacco leaf — the same basic oral delivery mechanism, the same use pattern, the same position in a harm reduction framework relative to cigarettes. Countries considering how to regulate pouches have available to them the Swedish experience as evidence that this product category can coexist with declining smoking rates and improving tobacco-related health outcomes.
Why has the Swedish lesson not been more influential in global policy? Several factors help explain the gap. The European Union’s ban on snus (other than in Sweden) has prevented the Swedish experience from replicating across the bloc. Ideological commitments in parts of the public health community to the goal of eliminating all nicotine use — rather than eliminating combustible tobacco specifically — have made the harm reduction framing politically uncomfortable. And the tobacco industry’s historical involvement in snus has created associations that make some advocates reluctant to embrace the product’s track record.
None of these explanations are sufficient justification for ignoring what Sweden has shown is possible. The country’s success should be the starting point for any serious conversation about nicotine harm reduction policy, not a footnote to debates that consistently arrive at more restrictive conclusions.
